In today's ACT Brief, we examine operational RBQM enhanced by AI, how statisticians ensure responsible data use across ...
In a recent video interview with Applied Clinical Trials, Sam Hinsley, statistics manager at Phastar, discussed the critical ...
Agentic AI can achieve >80% precision in discrepancy detection, enabling depth-first listing review that reduces variability, ...
Late-stage productivity improved in 2025, but total clinical development duration rose to 10 years, indicating non-structural ...
In this video interview, Sam Hinsley, statistics manager at Phastar, reflects on why she chose a career in clinical trials ...
In this conversation between Rebecca Johnson, PhD, ACT EAB member and clinical research recruitment and inclusion executive ...
In today's ACT Brief, we explore how diversity is embedded across trial planning at Merck, integration of patient-reported ...
In this Q&A, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how clinical ...
In today's ACT Brief, we examine cost models for imaging infrastructure in clinical trials, how community relationships ...
In today's ACT Brief, we examine leadership instability and regulatory uncertainty during Makary's FDA tenure, how lived ...
FDA Commissioner Marty Makary, MD, MPH, resigned Tuesday, according to The Associated Press, just 13 months after being ...
A multidisciplinary pre-review and single collaborative decision meeting replaces sequential NDA review, with FDA retaining discretion to extend timelines for ambiguity, incompleteness, or complexity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results